Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sikarin PCLBKK:SKR-R -0.63%90 Days Sales Outstanding is 27.25 as of Jun. 2026, which is 1% below its 10-year median of 27.58. GuruFocus rates BKK:SKR-R with a GF Score™ of 90/100 and a GF Value™ of ฿8.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 660 Healthcare Providers & Services companies, Sikarin PCL ranks better than 70.76% on this metric.
Sikarin PCL's average Accounts Receivable for the
three
months ended in Jun. 2026 was ฿408 Mil. Sikarin PCL's Revenue for the
three
months ended in Jun. 2026 was ฿1,367 Mil.
Hence, Sikarin PCL's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 27.25.
The historical rank and industry rank for Sikarin PCL's Days Sales Outstanding or its related term are showing as below:
BKK:SKR-R'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.78 Med: 27.58 Max: 35.9
Current: 28.75
During the past 13 years, Sikarin PCL's highest Days Sales Outstanding was 35.90. The lowest was 20.78. And the median was 27.58.
BKK:SKR-R's Days Sales Outstanding is ranked better than 70.76% of 660
companies
in the Healthcare Providers & Services industry
Industry Median: 45.78
vs BKK:SKR-R: 28.75
Sikarin PCL's Days Sales Outstanding
increased
from Jun. 2025 (27.17) to Jun. 2026 (27.25).
Sikarin PCL (BKK:SKR-R) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sikarin PCL Days Sales Outstanding Related Terms
Sikarin PCL Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sikarin PCL's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SKR-R vs HCA, THC, DVA: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Sikarin PCL's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sikarin PCL (BKK:SKR-R) has a Days Sales Outstanding of 27.25 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sikarin PCL and its competitors. This is near median its historical median of 27.58. Over the past decade, Sikarin PCL's Days Sales Outstanding has ranged from 20.78 to 35.90. According to the industry distribution chart, Sikarin PCL ranks #193 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 29.2%.
Is Sikarin PCL's Days Sales Outstanding too high?
Sikarin PCL's current Days Sales Outstanding of 27.25 is near median its 10-year median of 27.58. Over the past 10 years, this metric has ranged from a low of 20.78 to a high of 35.90. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.78. Sikarin PCL's value of 27.25 is 40.5% below this industry median. Based on the distribution chart, Sikarin PCL ranks #193 out of 660 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's Days Sales Outstanding compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #193 out of 660 companies for Days Sales Outstanding. This puts Sikarin PCL in the upper half of its industry. The industry median Days Sales Outstanding is 45.78. Sikarin PCL's value of 27.25 is 40.5% below this benchmark. Historically, Sikarin PCL's own Days Sales Outstanding has ranged from 20.78 to 35.90 over the past decade. While the company's 10-year median is 27.58 vs. the industry median of 45.78, Sikarin PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.78, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current Days Sales Outstanding of 27.25 is 40.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sikarin PCL and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current Days Sales Outstanding is 27.25, which is near median its own 10-year median of 27.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR-R) is currently considered Fairly Valued. The stock's GF Value™ is ฿8.11, compared to a current price of ฿7.85 — trading 3.2% below its estimated fair value. The current Days Sales Outstanding is 27.25, which is near median its 10-year median of 27.58 and 40.5% below the Healthcare Providers & Services industry median of 45.78. Sikarin PCL's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR-R), the current Days Sales Outstanding is 27.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.85 is trading 3.2% below its estimated GF Value™ of ฿8.11.
GuruFocus considers Sikarin PCL to be Fairly Valued.
Key valuation signals for BKK:SKR-R:
Days Sales Outstanding: 27.25 (near median its 10-year median of 27.58)
GF Value™: ฿8.11 vs. price of ฿7.85 (3.2% below fair value)
Industry Position: 40.5% below the Healthcare Providers & Services median (#193 of 660)
No single metric tells the full story. See the BKK:SKR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR-R
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR-R has been successfully added to your 
